24 November 2025: EXACT Therapeutics AS ("EXACT Tx" or the "Company") announces
that the Company as of today has introduced a new long-term incentive program in
the form of award of share options, each giving the right to purchase one share
in the Company at a strike price to be determined by the board of directors of
the Company, and with settlement in either shares in the Company or cash (the
"New Incentive Program"). The options will vest in tranches conditional upon the
participants continuous positions with the group, and are exercisable in
designated exercise windows, with the intention of following, inter alia, the
end of the quarter after the vesting periods. The Company wil issue a total of 1
069 643 options under the New Incentive Program.
The New Incentive Program replaces the current incentive program of the Company
(the "Current Incentive Program"). Thus, options held by certain primary
insiders of the Company under the Current Incentive Program will lapse
accordingly, while new options will be awarded to the respective participants,
including primary insiders, as further set out in the attached notifications of
trade.
This information is subject to the disclosure requirements in article 19 of the
EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading
Act.
For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com
About EXACT-Tx:
EXACT-Tx is a clinical-stage precision medicine company utilizing the power of
ultrasound and microbubbles to enable targeted drug delivery in oncology.
Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to
a wide range of therapeutic agents across a multitude of indications including
within oncology (chemotherapy, immunotherapy) and brain diseases.
www.exact-tx.com